Study shows chemoradiotherapy prior to surgery improves survival

Feb 28, 2011

Researchers from Boston University School of Medicine (BUSM) have found that patients with node negative T3 and T4 non-small lung cancer who underwent chemotherapy before surgery had more than three times the survival rate than patients who only underwent surgery. These findings currently appear on-line in the Journal of Thoracic and Cardiovascular Surgery.

The study looked at a total of 110 patients who underwent surgical resection for invasive T3 and T4 non-small between 1979 and 2008. Forty-seven patients received neoadjuvant and concurrent high dose radiation therapy prior to surgery (Chemo-RT group). Sixty-three patients underwent surgery without receiving induction chemoradiotherapy (Surg group) but instead received neoadjuvant radiation, adjuvant radiation, adjuvant chemotherapy, adjuvant chemoradiotherapy or brachytherapy. Seventeen received surgery alone.

Median survival was greatest for those who received surgery and neoadjuvant chemoradiotherapy (90 months) compared with patients in the Surg group who also received adjuvant external radiation therapy (25 months), surgery and neoadjuvant external radiation (19 months) or surgery alone (19 months).

"Our study found of node-negative invasive T3 and T4 NSCLC with induction chemoradiotherapy may significantly improve survival," said lead author Benedict Daly, MD, chair of the department of cardiothoracic surgery at BUSM.

Explore further: Omega-3 hope for cancer patients

Related Stories

Recommended for you

Omega-3 hope for cancer patients

43 minutes ago

The chemistry involved in designing drugs with the potential to treat cancer is complex and finicky. The placement of a single atom can be the difference between a cancer killer and a useless bystander. And ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.